Evidence map›Paper›PMID 29921600›Full record

ArticleThe Journal of cell biology2018

Mammary molecular portraits reveal lineage-specific features and progenitor cell vulnerabilities.

Alison E Casey, Ankit Sinha, Rajat Singhania, Julie Livingstone, Paul Waterhouse, Pirashaanthy Tharmapalan, Jennifer Cruickshank, Mona Shehata, Erik Drysdale, Hui Fang and 17 more

Open access · hybridAbstract read
In one paragraph

Article in The Journal of cell biology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
2.4field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 53 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. PDGFRαNature communications · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors at 4 institutions in 2 countries.

Alison E CaseyPrincess Margaret Cancer Centre, Toronto, ON, Canada.
Ankit SinhaPrincess Margaret Cancer Centre, Toronto, ON, Canada.
Rajat SinghaniaPrincess Margaret Cancer Centre, Toronto, ON, Canada.
Julie LivingstoneInformatics and Biocomputing Program, Ontario Institute for Cancer Research, Toronto, ON, Canada.ORCID 0000-0002-8424-3768
Paul WaterhousePrincess Margaret Cancer Centre, Toronto, ON, Canada.ORCID 0000-0001-8745-5224
Pirashaanthy TharmapalanPrincess Margaret Cancer Centre, Toronto, ON, Canada.
Jennifer CruickshankPrincess Margaret Cancer Centre, Toronto, ON, Canada.
Mona ShehataPrincess Margaret Cancer Centre, Toronto, ON, Canada.
Erik DrysdaleInformatics and Biocomputing Program, Ontario Institute for Cancer Research, Toronto, ON, Canada.
Hui FangPrincess Margaret Cancer Centre, Toronto, ON, Canada.
Hyeyeon KimPrincess Margaret Cancer Centre, Toronto, ON, Canada.
Ruth IsserlinThe Donnelly Centre, University of Toronto, Toronto, ON, Canada.
Swneke BaileyPrincess Margaret Cancer Centre, Toronto, ON, Canada.
Tiago MedinaPrincess Margaret Cancer Centre, Toronto, ON, Canada.
Genevieve DebloisPrincess Margaret Cancer Centre, Toronto, ON, Canada.
Yu-Jia ShiahInformatics and Biocomputing Program, Ontario Institute for Cancer Research, Toronto, ON, Canada.
Dalia Barsyte-LovejoyStructural Genomics Consortium, University of Toronto, Toronto, ON, Canada.
Stefan HoferPrincess Margaret Cancer Centre, Toronto, ON, Canada.
Gary BaderThe Donnelly Centre, University of Toronto, Toronto, ON, Canada.ORCID 0000-0003-0185-8861
Mathieu LupienPrincess Margaret Cancer Centre, Toronto, ON, Canada.
Cheryl ArrowsmithPrincess Margaret Cancer Centre, Toronto, ON, Canada.
Stefan KnappNuffield Department of Clinical Medicine, Structural Genomics Consortium, University of Oxford, Oxford, UK.
Daniel De CarvalhoPrincess Margaret Cancer Centre, Toronto, ON, Canada.
Hal BermanPrincess Margaret Cancer Centre, Toronto, ON, Canada.
Paul C BoutrosInformatics and Biocomputing Program, Ontario Institute for Cancer Research, Toronto, ON, Canada.
Thomas KislingerPrincess Margaret Cancer Centre, Toronto, ON, Canada.ORCID 0000-0003-3525-5540
Rama KhokhaPrincess Margaret Cancer Centre, Toronto, ON, Canada rama.khokha@uhnresearch.ca.ORCID 0000-0002-6028-1524
Princess Margaret Cancer Centre · CAUniversity of Toronto · CAOntario Institute for Cancer Research · CAUniversity of Oxford · GB

Funding

TR&D 3 - Network Guided Machine LearningP41GM103504 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI IDEKER, TREY · 2012 to 2024
$17.3M
Cytoscape: A Modeling Platform for Biomolecular NetworksR01GM070743 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI IDEKER, TREY · 2004 to 2016
$5.7M
Cytoscape: A Modeling Platform for Biomolecular NetworksR01HG009979 · NHGRI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI IDEKER, TREY · 2017 to 2021
$3.5M
CIHRNHGRI NIH HHS R01 HG009979NIGMS NIH HHS P41 GM103504
6 · The paper itself

Abstract

The mammary epithelium depends on specific lineages and their stem and progenitor function to accommodate hormone-triggered physiological demands in the adult female. Perturbations of these lineages underpin breast cancer risk, yet our understanding of normal mammary cell composition is incomplete. Here, we build a multimodal resource for the adult gland through comprehensive profiling of primary cell epigenomes, transcriptomes, and proteomes. We define systems-level relationships between chromatin-DNA-RNA-protein states, identify lineage-specific DNA methylation of transcription factor binding sites, and pinpoint proteins underlying progesterone responsiveness. Comparative proteomics of estrogen and progesterone receptor-positive and -negative cell populations, extensive target validation, and drug testing lead to discovery of stem and progenitor cell vulnerabilities. Top epigenetic drugs exert cytostatic effects; prevent adult mammary cell expansion, clonogenicity, and mammopoiesis; and deplete stem cell frequency. Select drugs also abrogate human breast progenitor cell activity in normal and high-risk patient samples. This integrative computational and functional study provides fundamental insight into mammary lineage and stem cell biology.

Indexed as

AnimalsBreast NeoplasmsCell LineageCell Line, TumorDNA MethylationDNA, NeoplasmEpigenesis, GeneticEpigenomicsHumansMiceMice, TransgenicNeoplastic Stem CellsProgesteroneProteomeRisk FactorsRNA, NeoplasmDNA, NeoplasmProgesteroneProteomeRNA, NeoplasmTrp53 protein, mouseTumor Suppressor Protein p53

Identifiers

PMID29921600
PMCPMC6080920
OpenAlexW2809422028

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.